Patient outcomes based on prognostic risk groups in METEOR, a randomized phase 3 study of cabozantinib (cabo) versus everolimus (eve) in patients (...

Date 26 November 2016
Event European Multidisciplinary Meeting on Urological Cancers (EMUC) 2016
Session Oral presentations of the 6 best abstracts
Topics Renal Cell Cancer
Anticancer Agents
Biological Therapy
Presenter T. Powles